ArticleCancer cell2021
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 94 citations in OpenAlex.
- Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Trial
- HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects.Science China. Life sciences · 2026Review
- HER2 Alterations in Squamous Cell Lung Cancer: Biology, Therapeutic Landscape, and Emerging Precision Approaches.Cancers · 2026Review
- Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterations.Cell reports · 2026Article
- ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging.Cell · 2026Article
- Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.Molecular oncology · 2026Article
- Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies.Journal of hematology & oncology · 2026Review
- LINE-1 retrotransposition modulates metabolic stress and promotes cuproptosis resistance in lung squamous cell carcinoma by disrupting mitochondrial membrane homeostasis.Journal of translational medicine · 2026Article
- Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.Oncogene · 2026Article
- HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade.Acta pharmacologica Sinica · 2026Article
- Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.Cancer discovery · 2026Article
- PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Luteolin and its derivatives: modulation of epithelial-mesenchymal transition in fibrosis and cancer.Frontiers in pharmacology · 2026Review
- Histone lysine demethylases in breast cancer: molecular mechanisms, biological functions, and therapeutic intervention.Molecular cancer · 2025Review
- High-throughput characterization of 5886 HER2 variants identifies 112 new in cellulo gain-of-function mutations.Genomics · 2025Article
- Single-cell profiling of ERBB family receptors identifies ERBB3 as a key regulator in head and neck squamous cell carcinoma progression.Discover oncology · 2025Article
- Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer.JCI insight · 2025Article
- Silver Jubilee of HER2 targeting: a clinical success in breast cancer.Journal of the National Cancer Center · 2025Review
- Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors.NPJ precision oncology · 2025Article
- Immune infiltration related PRDX4 facilitates the malignant features and drug resistance of breast cancer.Scientific reports · 2025Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 7 institutions in 4 countries.
Ariella B HankerUTSW Simmons Comprehensive Cancer Center, Dallas, 5323 Harry Hines Boulevard, TX 75390, USA; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: ariella.hanker@utsouthwestern.edu.
Benjamin P BrownChemical and Physical Biology Program, Center for Structural Biology, and Medical Scientist Training Program, Vanderbilt University, Nashville, TN 37240, USA.
Jens MeilerDepartment of Chemistry and Center for Structural Biology, Vanderbilt University, Nashville, TN 37240, USA; Institute for Drug Discovery, Leipzig University Medical School, Leipzig, SAC 04103, Germany.
Arnaldo MarínUTSW Simmons Comprehensive Cancer Center, Dallas, 5323 Harry Hines Boulevard, TX 75390, USA; Doctoral Program in Medical Sciences, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
Harikrishna S JayanthanDepartment of Chemistry and Center for Structural Biology, Vanderbilt University, Nashville, TN 37240, USA.
Dan YeUTSW Simmons Comprehensive Cancer Center, Dallas, 5323 Harry Hines Boulevard, TX 75390, USA.
Chang-Ching LinUTSW Simmons Comprehensive Cancer Center, Dallas, 5323 Harry Hines Boulevard, TX 75390, USA.
Hiroaki AkamatsuUTSW Simmons Comprehensive Cancer Center, Dallas, 5323 Harry Hines Boulevard, TX 75390, USA.
Kyung-Min LeeUTSW Simmons Comprehensive Cancer Center, Dallas, 5323 Harry Hines Boulevard, TX 75390, USA; Department of Life Sciences, College of Natural Science, Hanyang University, Seoul 04736, Republic of Korea.
Sumanta ChatterjeeUTSW Simmons Comprehensive Cancer Center, Dallas, 5323 Harry Hines Boulevard, TX 75390, USA.
Dhivya R SudhanUTSW Simmons Comprehensive Cancer Center, Dallas, 5323 Harry Hines Boulevard, TX 75390, USA.
Alberto ServettoUTSW Simmons Comprehensive Cancer Center, Dallas, 5323 Harry Hines Boulevard, TX 75390, USA.
Monica Red BrewerDepartment of Chemistry and Center for Structural Biology, Vanderbilt University, Nashville, TN 37240, USA.
James P KochDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Jonathan H SheehanDivision of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Jie HeFoundation Medicine, Cambridge, MA 02141, USA.
Alshad S LalaniPuma Biotechnology, Inc., Los Angeles, CA 90024, USA.
Carlos L ArteagaUTSW Simmons Comprehensive Cancer Center, Dallas, 5323 Harry Hines Boulevard, TX 75390, USA; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Harold C. Simmons Comprehensive Cancer CenterVanderbilt University · USSouthwestern Medical Center · USFoundation Medicine (United States)Puma Biotechnology (United States) · USVanderbilt University Medical Center · USWashington University in St. Louis · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MUT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MMedical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8MRole of HER2 mutations in breast cancer progression and response to targeted therapiesR01CA224899 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ARTEAGA, CARLOS L · 2018 to 2022
$1.8MHigh-Performance Computer Cluster for Biomedical ResearchS10OD023680 · OD · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2017 to 2017
$587kHybrid Methods for Prediction and Design of Novel Human Influenza AntibodiesR56AI110750 · NIAID · VANDERBILT UNIVERSITY · PI CROWE, JAMES E, MEILER, JENS · 2014 to 2014
$433kTargeting receptor tyrosine kinases with novel methods in computer-aided drug discovery for the treatment of fibrotic renal diseaseF30DK118774 · NIDDK · VANDERBILT UNIVERSITY · PI BROWN, BENJAMIN PATRICK · 2018 to 2021
$162kNCI NIH HHS P30 CA068485NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA224899NIAID NIH HHS R56 AI110750NIDDK NIH HHS F30 DK118774NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM152284NIH HHS S10 OD023680
Abstract
Activating mutations in HER2 (ERBB2) drive the growth of a subset of breast and other cancers and tend to co-occur with HER3 (ERBB3) missense mutations. The HER2 tyrosine kinase inhibitor neratinib has shown clinical activity against HER2-mutant tumors. To characterize the role of HER3 mutations in HER2-mutant tumors, we integrate computational structural modeling with biochemical and cell biological analyses. Computational modeling predicts that the frequent HER3
Indexed as
Gain of Function MutationAminopyridinesAnimalsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCell Line, TumorDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleHumansMiceMice, NudeMolecular Docking SimulationMolecular Dynamics SimulationMorpholinesPhosphatidylinositol 3-KinasesAminopyridinesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesERBB3 protein, humanMorpholinesneratinibNVP-BKM120Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsQuinolinesReceptor, ErbB-3Trastuzumabbreast cancerHER2HER3molecular dynamicsneratinibpersonalized structural biologyPI3Kprecision oncologyRosetta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.